FGFR2 and infantile convulsions and choreoathetosis: Notably, pemigatinib and infigratinib, selective but reversible inhibitors of FGFR1-3, bind competitively to the ATP pocket within the kinase domain and have been effectively used to treat iCCA with positive FGFR2 fusion/rearrangement [34].